MX2015009403A - Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox. - Google Patents

Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox.

Info

Publication number
MX2015009403A
MX2015009403A MX2015009403A MX2015009403A MX2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A MX 2015009403 A MX2015009403 A MX 2015009403A
Authority
MX
Mexico
Prior art keywords
compounds
compound
compositions
oxidative stress
pathological conditions
Prior art date
Application number
MX2015009403A
Other languages
English (en)
Inventor
Gojon Romanillos Gabriel
Original Assignee
Nuevas Alternativas Naturales Thermafat S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/751,429 external-priority patent/US20130136725A1/en
Application filed by Nuevas Alternativas Naturales Thermafat S A P I De C V filed Critical Nuevas Alternativas Naturales Thermafat S A P I De C V
Publication of MX2015009403A publication Critical patent/MX2015009403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Alteraciones de homeostasis redox en mamíferos forman la base de un número de síntomas, síndromes y enfermedades, incluyendo SIDA y cáncer, los cuales pueden ser tratados exitosamente por administración a un mamífero de cantidades terapéuticamente efectivas de compuestos de sulfuro y/o compuestos de tiosulfato y/o compuestos de tionita y/o compuestos de tionato y/o especies químicas capaces de proporcionar a un sujeto en necesidad de ello un compuesto de sulfuro, compuesto de tiosulfato, compuesto de tionita, o compuesto de tionato. Las composiciones únicas de esta invención contienen una o más "sustancias de azufre activo" en combinación entre sí o con otros agentes terapéuticos. La invención también abarca los modos de administración variables de las sustancias terapéuticas. En particular, un método novedoso para combinar ingredientes activos con celulosa húmeda se proporciona, el cual permite que la celulosa húmeda funcione como un vehículo entérico.
MX2015009403A 2013-01-28 2014-01-28 Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox. MX2015009403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/751,429 US20130136725A1 (en) 2002-06-19 2013-01-28 Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
PCT/MX2014/000029 WO2014116097A2 (es) 2013-01-28 2014-01-28 Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox

Publications (1)

Publication Number Publication Date
MX2015009403A true MX2015009403A (es) 2017-07-04

Family

ID=51228167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009403A MX2015009403A (es) 2013-01-28 2014-01-28 Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox.

Country Status (10)

Country Link
EP (1) EP2949332A4 (es)
JP (1) JP2016508996A (es)
KR (1) KR20160140331A (es)
CN (1) CN105228633A (es)
AU (1) AU2014210447A1 (es)
BR (1) BR112015017440A2 (es)
CA (1) CA2898596A1 (es)
HK (1) HK1217175A1 (es)
MX (1) MX2015009403A (es)
WO (1) WO2014116097A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200083509A (ko) 2017-10-25 2020-07-08 4틴4 파마슈티컬스 게엠베하 특이적 dpp3-에피토프에 대하여 지시되고 이에 결합하는 dpp3 결합제 및 산화적 스트레스와 연관되는 질환 / 급성 병태의 예방 또는 치료에서의 그의 용도
WO2020147830A1 (en) * 2019-01-19 2020-07-23 Goldred Nanobiotech Co., Ltd. Ocular lens, pharmaceutical composition, and uses thereof
WO2021185786A1 (en) 2020-03-16 2021-09-23 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
JPS59118709A (ja) 1982-12-27 1984-07-09 Suntory Ltd 効力を増強しかつ低毒化せしめた抗腫瘍組成物
DE3419686A1 (de) 1983-05-26 1984-11-29 T and R Chemicals, Inc., Clint, Tex. Verwendung einer zusammensetzung mit therapeutischer wirksamkeit
IL81166A (en) 1987-01-05 1990-03-19 Kaplan Ephraim Pharmaceutically active combination comprising an ionic vanadium compound and thiosulfate or sulfite compound and optionally selenium
US8361514B2 (en) * 2002-06-19 2013-01-29 Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
JP5063878B2 (ja) * 2005-08-30 2012-10-31 扶桑薬品工業株式会社 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
CA2767168C (en) * 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions

Also Published As

Publication number Publication date
WO2014116097A2 (es) 2014-07-31
JP2016508996A (ja) 2016-03-24
AU2014210447A1 (en) 2015-08-20
WO2014116097A3 (es) 2014-12-04
EP2949332A4 (en) 2016-07-27
BR112015017440A2 (pt) 2017-07-11
HK1217175A1 (zh) 2016-12-30
CA2898596A1 (en) 2014-07-31
EP2949332A2 (en) 2015-12-02
CN105228633A (zh) 2016-01-06
KR20160140331A (ko) 2016-12-07

Similar Documents

Publication Publication Date Title
BR112015023747A2 (pt) métodos para tratar inflamação, doenças autoimunes e dor
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
MX2015009403A (es) Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox.
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
BR112015022197A2 (pt) tratamento de cataplexia
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA201170349A1 (ru) Модуляторы mif
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX2022001778A (es) Metodos para tratar esquizofrenia.
WO2015009726A3 (en) Medical uses of cd38 agonists
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
PH12015501002A1 (en) Treatment of cancer with pomalidomide in a renally impaired subject
DK2714888T3 (da) Rekombinant gær
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
MA38925B1 (fr) Dérivés de phénylalanine substitués
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов